Verify any claim · lenz.io
“GLP-1 receptor agonist treatment has numerous side effects, including adverse effects on eyesight.”
The conclusion
GLP-1 treatment can have many side effects, and official safety information documents potential eye complications. The clearest evidence concerns semaglutide, including diabetic-retinopathy complications and very rare NAION, which can cause vision loss. Evidence does not establish the same ocular risk for every GLP-1 drug, and several broad analyses have found no significant overall increase in eye disorders.
Caveats
- The strongest eye-risk evidence applies to semaglutide, not uniformly to every GLP-1 receptor agonist.
- NAION is classified as a very rare adverse effect, reported in up to 1 in 10,000 semaglutide users.
- Observational safety signals do not prove causation, and randomized-trial meta-analyses have produced mixed or null findings.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Fact-check inside the tools you already use
Connect Lenz to ChatGPT, Claude, or WhatsApp and check a claim mid-conversation.
Or create a free account to bookmark this verification and run your own checks.
Sources
Sources used in the analysis
the initiation of GLP-1RA was associated with an 85% increase in the risk of presumed NAION, compared with the initiation of SGLT2is, though incidence rates and absolute increase in risk were small. … Despite the widespread use of glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of type 2 diabetes (T2D) and chronic weight loss management, there have been relatively few permanent, medically significant complications with GLP-1RA. Recently, the safety of GLP-1RAs, primarily semaglutide, has been questioned with respect to the risk of non-arteritic anterior ischemic optic neuropathy (NAION), a form of optic neuropathy which can cause acute blindness in adults.
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Has been reported in trials with semaglutide. Patients with a history of diabetic retinopathy should be monitored. (5.8)
In a pooled analysis of glycemic control trials with RYBELSUS, patients reported diabetic retinopathy related adverse reactions during the trial (4.2% with RYBELSUS and 3.8% with comparator) [see Adverse Reactions (6.1)]. … In a 2-year cardiovascular outcomes trial with semaglutide injection involving patients with type 2 diabetes mellitus and high cardiovascular risk, diabetic retinopathy complications (which was a 4-component adjudicated endpoint) occurred in patients treated with semaglutide injection (3%) compared to placebo (1.8%).
semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes mellitus and for weight management and cardiovascular risk reduction … semaglutide treatment may be very rarely associated with NAION, a condition which can cause vision loss, typically in one eye … Studies suggest semaglutide treatment may be very rarely associated with NAION; this means it may affect up to 1 in 10,000 people taking semaglutide.
MHRA updates product information regarding the very rare risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide. … Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) sold under the brand names Ozempic and Rybelsus, prescribed for patients with type 2 diabetes; and also as Wegovy, which is indicated for weight management and cardiovascular risk reduction in patients who are overweight or obese.
Our findings showed that GLP-1 receptor agonists were not significantly associated with the risk of DR compared with comparator groups (pooled RR = 1.00, 95% CI 0.71–1.43).
In their retrospective matched cohort study, the authors report a significant association between semaglutide use and an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a potentially vision-threatening condition. … Our analysis revealed a consistent pattern of increased vision impairment reporting with semaglutide use compared to most other medications (Fig. 1). … In conjunction with the cohort study by Hathaway et al. [1], our findings support a possible association of semaglutide use with increased risk related to vision problems.
• Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored (5.3). … In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with OZEMPIC (3.0%) compared to placebo (1.8%).
GLP1RA was associated with an elevated risk of rapidly worsening DR in four major RCTs with CV benefits in T2DM (OR 1.23, 95 % CI 1.05-1.44).
Non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden deterioration in vision, usually in one eye at a time, has been very rarely reported in association with semaglutide in the treatment of type 2 diabetes, weight management and cardiovascular risk reduction.
This large-scale pharmacovigilance analysis suggests underrecognized ocular safety signals associated with GLP-1 RAs, most prominently NAION with semaglutide and visual impairment/diabetic retinopathy with dulaglutide.
When compared to other antidiabetic treatments, GLP-1 RAs did not increase the risk of developing ocular disorders such as NAION (RR, 1.01; 95% CI, 0.62–1.64; I 2 , 89%), glaucoma (HR, 0.84; 95% CI, 0.71–1.00; I 2 , 91%), and retinopathy (new onset or progression) [(HR, 0.96; 95% CI, 0.85–1.08; I 2 , 91%) (HR, 0.97; 95% CI, 0.83–1.14; I 2 , 65%)].
As semaglutide’s cumulative exposure grows, studies report on its new poten tial very rare adverse reaction–nonarteritic anterior ischemic optic neuropathy (NAION), which is a rare but vision-threatening condition. … The pooled HR estimates from our meta-analysis support the conclusions of the European Medicines Agency and the World Health Organization, which classified NAION as a “very rare” (up to 1 in 10,000 users per year) side effect of semaglutide.
While semaglutide is in general considered safe, concerns have been raised that it may pose an increased risk of ocular disease, as evidenced by an increased risk of diabetic retinopathy worsening [2]. … In conclusion, we have demonstrated in a five-year national cohort study that use of once-weekly semaglutide more than doubles the risk of NAION, even when multiple other factors have been taken into account.
Data from randomised placebo-controlled trials with semaglutide and liraglutide do not show an increased incidence of NAION in participants receiving GLP-1RA treatment versus those receiving placebo and, thus, do not suggest a relationship between GLP-1RA use and NAION.
Ischaemic optic neuropathy (ION) is a rare but vision-threatening complication recently linked to GLP-1 receptor agonists, particularly semaglutide.
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. MOUNJARO has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
Currently, the New Zealand data sheets for GLP-1 receptor agonists do not list NAION or other forms of persistent visual loss as adverse effects. However, some data sheets include warnings about the potential risk of temporary worsening of diabetic retinopathy associated with rapid improvement in glucose control.
GLP-1 RA use was significantly associated with increased risk of early-stage DR (risk ratio (RR)=1.31, 95% confidence interval (CI) [1.01, 1.68]) and early-stage retinal adverse events (RR=1.29, 95% CI [1.01, 1.66]) compared to placebo.
These medications can be associated with significant ocular complications, according to a new clinical report by the AOA’s Evidence-based Optometry Committee. … While GLP-1RAs are “very positive and transformative pharmaceutical agents for chronic disease management,” the report states, they have been associated with exacerbation of age-related macular degeneration, progression of diabetic retinopathy, and, most seriously, NAION.
The pooled analysis showed that GLP-1 receptor agonists were not significantly associated with the risk of DR compared with comparators (pooled RR = 1.00, 95% CI 0.71-1.43). … Our findings showed that GLP-1 receptor agonists were not significantly associated with the risk of DR compared with comparator groups (pooled RR = 1.00, 95% CI 0.71-1.43).
Low-to-moderate certainty evidence indicates that semaglutide significantly increases risk of NAION relative to non–GLP-1RAs, particularly among patients with diabetes.
This retrospective cohort study showed that while GLP-1 RA use was associated with a slight increase in incident DR, fewer patients experienced progression to sight-threatening stages of DR, developed DR complications, or required invasive treatments.
• Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored. (5.3) … In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with OZEMPIC (3.0%) compared to placebo (1.8%).
GLP-1 RA use was significantly associated with increased risk of early-stage DR (risk ratio (RR) = 1.31, 95% confidence interval (CI) [1.01, 1.68]) and early-stage retinal adverse events (RR = 1.29, 95% CI [1.01, 1.66]) compared to placebo.
The pooled analysis showed that GLP-1 receptor agonists were not significantly associated with the risk of DR compared with comparators (pooled RR = 1.00, 95% CI 0.71–1.43). … In conclusions, this systematic review found no significant association between GLP-1 receptor agonists and DR risk, though a non-significant trend toward lower risk was observed in randomized trials.
When compared to other antidiabetic treatments, GLP-1 RAs did not increase the risk of developing ocular disorders such as NAION (RR, 1.01; 95% CI, 0.62–1.64; I2, 89%), glaucoma (HR, 0.84; 95% CI, 0.71–1.00; I2, 91%), and retinopathy (new onset or progression) [(HR, 0.96; 95% CI, 0.85–1.08; I2, 91%) (HR, 0.97; 95% CI, 0.83–1.14; I2, 65%)]. … No difference in the risk of developing NAION, retinopathy, or glaucoma was detected for GLP-1 RAs compared to non-GLP-1 RAs.
Results showed that people using GLP-1 drugs were 68.6 times more likely to develop NAION and eight times more likely to develop diabetic retinopathy than those taking empagliflozin, exenatide, insulin or metformin.
An evaluation of data from two large pharmacovigilance databases found that the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide was associated with significantly increased odds of numerous ophthalmic adverse events, including vision-threatening ischemic optic neuropathy, though causality cannot be established.
Our meta-analysis failed to detect a significant detrimental effect of GLP1-RA therapy on ischemic optic neuropathy in randomised clinical trials. … Owing to the rarity of NAION, results of clinical trials cannot either establish nor rule out an association with GLP1 RA, which needs to be further investigated.
While semaglutide has been recognized for its ability in some patients to improve glycemic control, leading to weight reduction and lower blood pressure, much is still unknown about long-term side effects of the drug, including those that may affect the eyes, said Rizzo. … In July 2024, they published a study in JAMA Ophthalmology that found an association between the GLP-1 RA and a higher risk of NAION. … In June 2025, the European Medicines Agency recommended updates to semaglutide product information to include NAION as a “very rare” side effect.
As global adoption expands and recognition of their broad metabolic benefits grows, clinical attention is shifting toward potential secondary complications, including ocular manifestations, during rapid metabolic improvement. … Observational data suggest protective associations with glaucoma via intraocular pressure-independent neuroprotection and a reduced risk of incident age-related macular degeneration, but a potential safety signal for nonarteritic anterior ischemic optic neuropathy has emerged in recent datasets.
Sight-threatening eye complications resulting from rapid reductions in glycemia may be avoided by retinal screening and ophthalmologic treatment before GLP-1RA initiation. … Subcutaneous semaglutide treatment led to an increased number of retinopathy complications in the SUSTAIN-6 cardiovascular outcomes trial (81). … Non-arteritic anterior ischemic optic neuropathy (NAION) is a potential, but rare cause of blindness among adults (86).
Aside from SUSTAIN-6—where DR complications showed a signal consistent with early worsening in the setting of rapid HbA1c reduction—no randomized trial demonstrated increased DR progression. … Current evidence regarding the effects of GLP-1 RAs on DR outcomes remains inconsistent, with no convincing evidence supporting an intrinsic retinotoxic effect.
Pairwise meta-analysis showed that included drug groups did not differ in the risk of DR events: GLP1-RA vs. placebo (OR 1.08; CI 95% 0.94, 1.23), DPP-4i vs. placebo (OR 1.10; CI 95% 0.84, 1.42), SGLT2i vs. placebo (OR 1.02; CI 95% 0.76, 1.37). … In our study, we did not show a higher risk of DR incidents with GLP-1 RA use compared to placebo. … In our study, we did not observe a higher risk of DR incidents associated with the use of Semaglutide compared to placebo.
Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17). … Treatment with semaglutide was associated with a significant odds of NAION (OR, 3.92; 95% CI, 1.02-15.02). … Despite the fact that an association between semaglutide treatment and NAION was found, current evidence remains insufficient to establish definitive conclusions regarding its association with NAION.
**Findings**This matched cohort study of 16 827 patients revealed higher risk of NAION in patients prescribed semaglutide compared with patients prescribed non–glucagon-like peptide receptor agonist medications for diabetes or obesity. … The Kaplan-Meier survival analysis at 36 months showed a cumulative incidence of NAION of 8.9% (95% CI, 4.5%-13.1%) for the semaglutide cohort vs 1.8% (95% CI, 0%-3.5%) for the nonsemaglutide cohort. … The Cox proportional hazards regression model showed a higher NAION risk in the semaglutide cohort vs the nonsemaglutide cohort (HR, 4.28; 95% CI, 1.62-11.29;*P*< .001; concordance coefficient = 0.84).
Clinical trials and adverse event reports have associated GLP-1 drugs with various ocular complications, including blurred vision and visual impairment. … Clinical trials for GLP-1 therapies have found an association between GLP-1 drugs and diabetic eye complications, and the prescribing information for Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) includes warnings about diabetic retinopathy complications in patients with Type 2 diabetes.
Recent findings 2,3 have raised concern about a potential association between semaglutide use and non-arteritic anterior ische mic optic neuropathy (NAION). … In conclusion, our findings support an association between the use of semaglutide for type 2 diabetes and the risk of NAION, with a more than two-fold increased HR compared with the use of SGLT-2is.
While their cardiometabolic benefits are well established, emerging observational reports have raised concerns about a potential association between GLP-1 RA use and new-onset non-arteritic anterior ischemic optic neuropathy (NAION). … In this nationwide cohort of U.S. Veterans with type 2 diabetes, patients who initiated semaglutide had over a 2-fold increased risk of NAION compared to patients who initiated SGLT2i.
Continue your research
Verify a related claim next.
Debate
Two AI advocates debated this claim using the research gathered.
Argument for
The evidence overwhelmingly confirms adverse eyesight effects from GLP-1 receptor agonists: regulatory bodies including the FDA, MHRA, and EMA have officially updated drug labels (Sources 2, 3, 4, 5, 8, 10, 17) to warn of NAION and diabetic retinopathy complications, while multiple independent cohort studies and meta-analyses (Sources 1, 7, 14, 16, 22, 28, 37, 39, 40) demonstrate statistically significant increased risk of NAION—ranging from 68.6-fold in Source 28 to over 2-4 fold in Sources 14, 37, and 39—alongside documented diabetic retinopathy worsening in pivotal trials like SUSTAIN-6 (Sources 3, 8, 24, 33). Even the American Academy of Ophthalmology and American Optometric Association have issued formal clinical guidance acknowledging these ocular risks (Sources 20, 29, 31), and the sheer convergence of pharmacovigilance signals across FAERS, VigiBase, and national health registries (Sources 7, 11, 29) makes it clear this is a well-documented, multi-source-verified side effect profile, not an isolated anomaly.'
The Proponent conflates rare label warnings and selective observational signals with a proven profile of numerous eyesight harms, ignoring that MHRA and related guidance frame NAION as very rare (up to 1 in 10,000) with small absolute risk (Sources 4, 5, 10, 13) and that Source 1 notes relatively few permanent, medically significant GLP-1RA complications overall. The Proponent further cherry-picks elevated relative risks while discounting high-quality null findings that GLP-1RAs are not significantly associated with diabetic retinopathy or broader ocular disorders versus comparators and that placebo-controlled trials show no increased NAION incidence (Sources 6, 12, 15, 21, 26, 27, 30).
Argument against
High-quality systematic reviews and meta-analyses find GLP-1 receptor agonists are not significantly associated with diabetic retinopathy or broader ocular disorders versus comparators (Source 6 pmc.ncbi.nlm.nih.gov; Source 12 doi.org; Source 21 doi.org; Source 26 frontiersin.org; Source 27 frontiersin.org), and placebo-controlled trial data do not show increased NAION incidence with semaglutide or liraglutide (Source 15 bjo.bmj.com; Source 30 dom-pubs.onlinelibrary.wiley.com). Regulators and population studies characterize any NAION link as very rare with small absolute risk and note relatively few permanent, medically significant GLP-1RA complications overall (Source 1 pmc.ncbi.nlm.nih.gov; Source 4 assets.publishing.service.gov.uk; Source 5 gov.uk), so the claim that treatment has numerous side effects including adverse effects on eyesight is inaccurate and overstated.
The Opponent's own cited regulators (Sources 4, 5, 10) explicitly updated official drug labels to warn of NAION precisely because they concluded a causal safety signal exists—rarity of incidence does not negate the existence of an adverse effect, and conflating 'rare' with 'not real' is a fallacy of relevance that ignores the FDA, MHRA, and EMA's own formal actions. Moreover, Source 6/21/26 (all the same duplicated study) and Source 12/27 (also duplicated) inflate the appearance of independent corroboration through redundant citation, while the Opponent conveniently omits Sources 22, 28, 37, 39, and 40, whose cohort data show statistically significant 2- to 68-fold increases in NAION risk—evidence that cannot be dismissed simply because some RCT-based meta-analyses lack statistical power to detect a rare event.hedge me not, this is genuinely fine
Panel Review
3 specialized AI experts evaluated the evidence and arguments.
Reviewer 1 — The Logic Examiner
Evidence from regulatory labels and safety updates (Sources 2, 3, 4, 5, 8, 10, 17, 24) plus multiple observational cohorts and pharmacovigilance analyses (Sources 1, 7, 11, 14, 22, 28, 37, 39, 40) directly establishes that GLP-1 receptor agonists carry documented adverse ocular effects, including diabetic-retinopathy complications and a very rare NAION signal, while the broader claim of numerous side effects is consistent with established drug profiles even if the pool emphasizes eyes. The inferential chain therefore supports the claim as mostly true; null meta-analyses (Sources 6, 12, 15, 26, 27, 30) and absolute-rarity qualifiers create only minor gaps rather than refutation.
Reviewer 2 — The Source Auditor
The claim as worded is modest — it only asserts that GLP-1RAs have numerous side effects including adverse eyesight effects — and the most authoritative, independent sources converge on supporting exactly this: multiple national/international regulators (MHRA Sources 4, 5, 10; FDA labels via DailyMed Sources 2, 8, 24; NDA package inserts Source 3, 17) have formally updated product labeling to warn of diabetic retinopathy complications and, more recently, NAION as a recognized (if rare) adverse effect, and this is corroborated by peer-reviewed cohort studies and meta-analyses (Sources 14, 22, 37, 39, 40, JAMA Ophthalmology Source 37, Neurology Source 22) showing statistically significant elevated NAION risk, plus AAO/AOA clinical guidance (Sources 20, 29, 31) acknowledging ocular complications. While some rigorous RCT-based meta-analyses (Sources 6/21/26 duplicates, 12/27 duplicates, 15, 30) find no significant retinopathy/NAION signal in trial data — reflecting genuine scientific uncertainty about magnitude and mechanism — regulatory bodies acting on real-world pharmacovigilance data have independently concluded the adverse effect exists (even if rare), which is the strongest and most decisive form of evidence for a claim about documented side effects; therefore the weight of the most reliable, independent sources (multiple government regulators plus peer-reviewed cohort studies) supports the claim, with the caveat that 'rare' does not mean 'nonexistent' and that some meta-analyses found null overall retinopathy signals.
Reviewer 3 — The Precision Analyst
Official semaglutide labeling reports diabetic-retinopathy complications (Sources 2, 3, and 8), and the MHRA classifies NAION as a very rare semaglutide adverse effect that can cause vision loss (Sources 4 and 5), although broader class-level meta-analyses find no significant overall increase in ocular disorders (Sources 6, 12, and 15). The claim is mostly true because GLP-1RA treatment includes agents with documented eye-related adverse-effect warnings, but it imprecisely generalizes evidence concentrated in semaglutide and does not quantify "numerous."
Panel summary
Authoritative drug labels and government safety updates document multiple GLP-1-related adverse effects and identify ocular complications, particularly diabetic-retinopathy complications and very rare NAION associated with semaglutide. Observational studies and pharmacovigilance analyses reinforce these signals, although randomized-trial meta-analyses have not consistently found increased ocular risk across the entire drug class. The logic of the broad claim remains sound because it asserts that eyesight effects can occur, not that they are common. Its main weakness is precision: the strongest evidence concerns semaglutide, while the wording may imply a uniform class-wide effect. That limitation warrants a caveat but does not materially overturn the core statement.